Press Releases

July 28, 2021

Galaxy Medical Releases ECLIPSE-AF Remapping Data at Stanford Biodesign Retreat and Update on System Interoperability

SAN CARLOS, California, July 28, 2021 — Galaxy Medical announced today that the ECLIPSE-AF 90-day remapping data, presented at the Stanford BioDesign New Arrhythmia Technologies retreat, demonstrated durable lesions and chronic pulmonary vein isolation (PVI). Also, the company has recently treated patients in the same study using CE-Marked catheters and mapping systems from Boston Scientific, Biosense Webster and Abbott.... MORE
July 22, 2021

Galaxy Medical’s ECLIPSE-AF Study 90 Day Remapping Results to be Featured at the 2021 Stanford Biodesign New Arrhythmia Technologies Retreat

SAN CARLOS, California, July 22, 2021 — Galaxy Medical announced today that the 90 day remapping results of its ECLIPSE-AF study will be featured at the 2021 Stanford Biodesign New Arrhythmia Technologies Retreat on July 27th. Ante Ani, M.D., Electrophysiology Laboratory Director at University Clinical Hospital in Split, Croatia, and primary investigator of the study will deliver the presentation.... MORE
April 22, 2021

Galaxy Medical ECLIPSE-AF Study to be Featured in Innovative Technology Session at EHRA 2021 Annual Scientific Meeting

SAN CARLOS, California, April 22, 2021 — Galaxy Medical announced today that the acute results of its Europe-focused ECLIPSE-AF study will be featured during the upcoming EHRA Congress in a innovative Technology presentation on April 25th by Ante Ani , M.D., Electrophysiology Laboratory Director at University Clinical Hospital in Split, Croatia, and primary investigator of the study.... MORE
April 6, 2021

Galaxy Medical and Japan Lifeline Enter Distribution Agreement For Novel Pulsed Electric Field Focal Ablation Catheter

SAN CARLOS, California, April 6, 2021 — Galaxy Medical (Galaxy) and Japan Lifeline (JLL) today announced an exclusive distribution agreement for the ALPHA1 ablation catheter in the United States, developed by Japan Lifeline for use with the Galaxy CENTAURI™ Pulsed Electric Field (PEF) System. Under the terms of the agreement, Galaxy will pursue US regulatory approval for ALPHA1 in support of eventual commercialization of the CENTAURI PEF System.... MORE
March 16, 2021

Galaxy Medical Receives $18 Million from ATP to Advance Development of Its Novel Pulsed Electric Field Ablation Therapy for Cardiac Arrhythmias

SAN CARLOS, California, March 16, 2021 — ATP, a leader in life science venture capital, announced today $18M in Series A financing for its portfolio company Galaxy Medical, Inc. The funds are being used to advance the development of Galaxy’s flagship product CENTAURI™, which uses Pulsed Electric Field (PEF) technology... MORE
January 18, 2021

GALAXY Medical CENTAURI™ PEF Generator to be Used During Recorded Case Presentation at AF Symposium

SAN CARLOS, Calif., Jan. 18, 2021 — Galaxy Medical, a developer of Pulsed Electric Field (PEF) technology for the treatment of cardiac arrhythmias, today announced that its proprietary CENTAURI™ System will be featured in a recorded case presentation on Sunday January 31st during the upcoming AF Symposium... MORE
October 9, 2020

First Patients Treated with Galaxy Medical’s CENTAURI™ Pulsed Electric Field Cardiac Ablation System

Menlo Park, CA, October 9, 2020 — Galaxy Medical, (Galaxy), a developer of Pulsed Electric Field (PEF) technology for the treatment of cardiac arrhythmias, today announced that the first patients were successfully treated with the proprietary CENTAURI™ System by Dr. Ante Ani in Split, Croatia as part of the ECLIPSE-AF study. This multicenter trial is designed to assess the safety, efficacy, and interoperability of the Centauri System and is intended... MORE